In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium

Infections with carbapenem-resistant (CR) Gram-negative (GN) pathogens have increased in many countries worldwide, leaving only few therapeutic options. Cefiderocol (CFDC) is approved in Europe for the treatment of aerobic GN infections in adults with limited treatment options. This study evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Oueslati, Saoussen, Bogaerts, Pierre, Dortet, Laurent, Bernabeu, Sandrine, Ben Lakhal, Hend, Longshaw, Christopher, Glupczynski, Youri, Naas, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598183/
https://www.ncbi.nlm.nih.gov/pubmed/36290010
http://dx.doi.org/10.3390/antibiotics11101352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598183/
https://www.ncbi.nlm.nih.gov/pubmed/36290010
http://dx.doi.org/10.3390/antibiotics11101352

Ejemplares similares